Chemokines cooperate with TNF to provide protective anti-viral immunity and to enhance inflammation

[1]  S. Savvides,et al.  Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures , 2016, Nature Reviews Immunology.

[2]  R. Eisenberg,et al.  Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections , 2016, Cell.

[3]  L. Nolen,et al.  Extended Human-to-Human Transmission during a Monkeypox Outbreak in the Democratic Republic of the Congo , 2016, Emerging infectious diseases.

[4]  L. Sigal.  The Pathogenesis and Immunobiology of Mousepox. , 2016, Advances in immunology.

[5]  A. Alcamí,et al.  Immune modulation by virus-encoded secreted chemokine binding proteins. , 2015, Virus research.

[6]  A. Alcamí,et al.  Poxvirus-encoded TNF decoy receptors inhibit the biological activity of transmembrane TNF. , 2015, The Journal of general virology.

[7]  C. Nelson,et al.  Structural Conservation and Functional Diversity of the Poxvirus Immune Evasion (PIE) Domain Superfamily , 2015, Viruses.

[8]  Tracy E. Krouse,et al.  Redundant Function of Plasmacytoid and Conventional Dendritic Cells Is Required To Survive a Natural Virus Infection , 2015, Journal of Virology.

[9]  A. Alcamí,et al.  Comparative Biochemical and Functional Analysis of Viral and Human Secreted Tumor Necrosis Factor (TNF) Decoy Receptors* , 2015, The Journal of Biological Chemistry.

[10]  J. Yewdell,et al.  CXCR3 chemokine receptor enables local CD8(+) T cell migration for the destruction of virus-infected cells. , 2015, Immunity.

[11]  S. Shchelkunov,et al.  TNF binding protein of variola virus acts as a TNF antagonist at epicutaneous application. , 2015, Current pharmaceutical biotechnology.

[12]  R. Jacobs,et al.  TNFR2 and IL‐12 coactivation enables slanDCs to support NK‐cell function via membrane‐bound TNF‐α , 2014, European journal of immunology.

[13]  A. Bowie,et al.  Innate immune activation of NFκB and its antagonism by poxviruses. , 2014, Cytokine & growth factor reviews.

[14]  B. Barrell,et al.  The genome sequence of ectromelia virus Naval and Cornell isolates from outbreaks in North America , 2014, Virology.

[15]  C. Ware,et al.  The Lymphotoxin Network: orchestrating a type I interferon response to optimize adaptive immunity. , 2014, Cytokine & growth factor reviews.

[16]  S. Shchelkunov.  An Increasing Danger of Zoonotic Orthopoxvirus Infections , 2013, PLoS pathogens.

[17]  C. Maluquer de Motes,et al.  Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. , 2013, The Journal of general virology.

[18]  A. Alcamí,et al.  Crosstalk between the type 1 interferon and nuclear factor kappa B pathways confers resistance to a lethal virus infection. , 2013, Cell host & microbe.

[19]  M. Bronze,et al.  Clinical use of anti-TNF therapy and increased risk of infections , 2013, Drug, healthcare and patient safety.

[20]  D. Fremont,et al.  Subversion of cytokine networks by virally encoded decoy receptors , 2012, Immunological reviews.

[21]  A. Alcamí,et al.  Antibody Inhibition of a Viral Type 1 Interferon Decoy Receptor Cures a Viral Disease by Restoring Interferon Signaling in the Liver , 2012, PLoS pathogens.

[22]  Xinquan Wang,et al.  Structural Basis of Chemokine Sequestration by CrmD, a Poxvirus-Encoded Tumor Necrosis Factor Receptor , 2011, PLoS pathogens.

[23]  M. Bachmann,et al.  The Bidirectional Crosstalk between Human Dendritic Cells and Natural Killer Cells , 2011, Journal of Innate Immunity.

[24]  A. Alcamí,et al.  Poxviral TNFRs: properties and role in viral pathogenesis. , 2011, Advances in experimental medicine and biology.

[25]  G. Kollias,et al.  Attenuation of TNF-driven murine ileitis by intestinal expression of the viral immunomodulator CrmD , 2010, Mucosal Immunology.

[26]  M. Cornberg,et al.  Resistance to Vaccinia Virus Is Less Dependent on TNF under Conditions of Heterologous Immunity1 , 2009, The Journal of Immunology.

[27]  A. Alcamí,et al.  A Method for the Generation of Ectromelia Virus (ECTV) Recombinants: In Vivo Analysis of ECTV vCD30 Deletion Mutants , 2009, PloS one.

[28]  H. Baker,et al.  The Addition of Tumor Necrosis Factor plus Beta Interferon Induces a Novel Synergistic Antiviral State against Poxviruses in Primary Human Fibroblasts , 2008, Journal of Virology.

[29]  R. Eisenberg,et al.  The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination , 2008, The Journal of experimental medicine.

[30]  C. Benedict,et al.  Lymphotoxin-mediated crosstalk between B cells and splenic stroma promotes the initial type I interferon response to cytomegalovirus. , 2008, Cell host & microbe.

[31]  D. Fowell,et al.  Pathogen-imposed skewing of mouse chemokine and cytokine expression at the infected tissue site. , 2008, The Journal of clinical investigation.

[32]  L. Lanier,et al.  A Role for NKG2D in NK Cell–Mediated Resistance to Poxvirus Disease , 2008, PLoS pathogens.

[33]  Zhigang Zhou,et al.  TNFR1-induced NF-kappaB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells. , 2007, Cellular signalling.

[34]  A. Gambotto,et al.  Essential role of the TNF-TNFR2 cognate interaction in mouse dendritic cell-natural killer cell crosstalk. , 2007, Blood.

[35]  J. Corbett,et al.  Induction of Natural Killer Cell Responses by Ectromelia Virus Controls Infection , 2007, Journal of Virology.

[36]  G. McFadden,et al.  Immunopathogenesis of poxvirus infections: forecasting the impending storm , 2007, Immunology and cell biology.

[37]  T. Braciale,et al.  A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. , 2007, Vaccine.

[38]  B. Graham,et al.  Smallpox vaccines: Past, present, and future , 2006, The Journal of allergy and clinical immunology.

[39]  L. Sigal,et al.  Direct CD28 Costimulation Is Required for CD8+ T Cell-Mediated Resistance to an Acute Viral Disease in a Natural Host1 , 2006, The Journal of Immunology.

[40]  A. Alcamí,et al.  Pathogen-derived immunomodulatory molecules: future immunotherapeutics? , 2006, Trends in immunology.

[41]  S. Shchelkunov,et al.  Properties of the recombinant TNF-binding proteins from variola, monkeypox, and cowpox viruses are different , 2006, Biochimica et biophysica acta.

[42]  D. Venzon,et al.  Subunit Recombinant Vaccine Protects against Monkeypox1 , 2006, The Journal of Immunology.

[43]  Margarida Saraiva,et al.  A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Koichiro Nakamura,et al.  CCL28 production in HaCaT cells was mediated by different signal pathways from CCL27 , 2006, Experimental dermatology.

[45]  G. McFadden,et al.  Modulation of Tumor Necrosis Factor by Microbial Pathogens , 2006, PLoS pathogens.

[46]  T. Salazar-Mather,et al.  Cytokine and chemokine networks: pathways to antiviral defense. , 2006, Current topics in microbiology and immunology.

[47]  R. Buller,et al.  Ectromelia virus: the causative agent of mousepox. , 2005, The Journal of general virology.

[48]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[49]  Adeline R. Whitney,et al.  The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[50]  G. Karupiah,et al.  Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Atrasheuskaya,et al.  Protective effect of exogenous recombinant mouse interferon‐gamma and tumour necrosis factor‐alpha on ectromelia virus infection in susceptible BALB/c mice , 2004, Clinical and experimental immunology.

[52]  M. Caligiuri,et al.  NK cell and DC interactions. , 2004, Trends in immunology.

[53]  B. Moss,et al.  A Role for Tumor Necrosis Factor Receptor-2 and Receptor-interacting Protein in Programmed Necrosis and Antiviral Responses* , 2003, Journal of Biological Chemistry.

[54]  M. Danila,et al.  The genomic sequence of ectromelia virus, the causative agent of mousepox. , 2003, Virology.

[55]  G. McFadden,et al.  Poxviruses and immune evasion. , 2003, Annual review of immunology.

[56]  E. Pamer,et al.  TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. , 2003, Immunity.

[57]  M. Smyth,et al.  Functional interactions between dendritic cells and NK cells during viral infection , 2003, Nature Immunology.

[58]  Antonio Alcami,et al.  Viral mimicry of cytokines, chemokines and their receptors , 2003, Nature Reviews Immunology.

[59]  A. Alcamí,et al.  Inhibition of Type 1 Cytokine–mediated Inflammation by a Soluble CD30 Homologue Encoded by Ectromelia (Mousepox) Virus , 2002, The Journal of experimental medicine.

[60]  J. Panus,et al.  Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: A soluble, secreted CD30 homologue , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[61]  H. Soto,et al.  CCL27–CCR10 interactions regulate T cell–mediated skin inflammation , 2002, Nature Medicine.

[62]  Geoffrey L. Smith,et al.  Vaccinia virus CrmE encodes a soluble and cell surface tumor necrosis factor receptor that contributes to virus virulence. , 2002, Virology.

[63]  A. Alcamí,et al.  CrmE, a Novel Soluble Tumor Necrosis Factor Receptor Encoded by Poxviruses , 2001, Journal of Virology.

[64]  M. Feldmann,et al.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.

[65]  A. Alcamí,et al.  Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. , 1999, The Journal of general virology.

[66]  J. Panus,et al.  A third distinct tumor necrosis factor receptor of orthopoxviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[67]  A. Alcamí,et al.  Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. , 1998, Journal of immunology.

[68]  J. Peschon,et al.  Antiviral Activity of Tumor Necrosis Factor (TNF) Is Mediated via p55 and p75 TNF Receptors , 1997, The Journal of experimental medicine.

[69]  C. Smith,et al.  Cowpox virus genome encodes a second soluble homologue of cellular TNF receptors, distinct from CrmB, that binds TNF but not LT alpha. , 1996, Virology.

[70]  C. Smith,et al.  Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. , 1994, Virology.

[71]  W. Glasgow,et al.  Multigenic evasion of inflammation by poxviruses , 1994, Journal of virology.

[72]  G. McFadden,et al.  Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence. , 1991, Virology.

[73]  M. Kohonen-Corish,et al.  Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[74]  G. McFadden,et al.  T2 open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor. , 1991, Biochemical and biophysical research communications.

[75]  C. Mims.  ASPECTS OF THE PATHOGENESIS OF VIRUS DISEASES. , 1964, Bacteriological reviews.